Oxidative stress, inflammation and cardiovascular mortality in haemodialysis - Role of seniority and intravenous ferrotherapy: Analysis at 4 years of follow-up

Nephrology Dialysis Transplantation

Volumn 21, Issue 4, 2006, Pages 984-990

  Bayés, Beatriz ^a   Pastor, Mari Cruz ^a   Bonal, Jordi ^a   Foraster, Andreu ^a   Romero, Ramón ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

C reactive protein; Cardiovascular mortality; Haemodialysis; Oxidative stress

Indexed keywords

ALBUMIN; ANTIGEN; C REACTIVE PROTEIN; COPPER; ERYTHROPOIETIN; FERROUS GLUCONATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VITAMIN;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY TITER; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOLUMINESCENCE; CHRONIC INFLAMMATION; CONTROLLED STUDY; COPPER BLOOD LEVEL; CORRELATION ANALYSIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPTICAL DENSITY; OXIDATIVE STRESS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; FEMALE; FERRIC COMPOUNDS; FOLLOW-UP STUDIES; HEMATINICS; HUMANS; INFLAMMATION; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33645284688     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi294     Document Type: Article

References (18)

1. Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 2002; 13: 1918-1927
2. Bayés B, Pastor MC, Bonal J, Juncà J, Romero R. Homocysteine and lipid peroxidation in haemodialysis: Role of folinic acid and vitamin E. Nephrol Dial Transplant 2001; 16: 2172-2175
3. Santoro A, Mancini E. Cardiac effects of chronic inflammation in dialysis patients. Nephrol Dial Transplant 2002; 17: 10-15
4. Wanner C, Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002; 17: 29-32
5. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538
6. Bayés B, Pastor MC, Bonal J et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 106-112
7. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 [Suppl 5]: 17-18
8. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511
9. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141
10. EBPG for haemodialysis. Nephrol Dial Transplant 2002; 17 [Suppl 7]: 100-101
11. Strandberg TE, Tilvis RS. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol 2000; 20: 1057-1060
12. Drüeke TB, Khoa TN, Massy ZA et al. Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int Suppl 2001; 78: S114-5119
13. Maggi E, Bellazzi R, Falaschi F et al. Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 1994; 45: 876-883
14. Holvoet P, Mertens A, Verhamme P et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001; 21: 844-848
15. Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911
16. Shoji T, Fukumoto M, Kimoto E et al. Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney Int 2002; 62: 2230-2237
17. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999; 14: 2680-2687
18. Sun Y, Stidley CA, Harford AM et al. Increased cardiovascular and infectious deaths in hemodialysis (HD) patients treated with high dose intravenous iron therapy. J Am Soc Nephrol 2002; 13: 434A